

1

2 **Cross-neutralizing activity against SARS-CoV-2 variants in COVID-19 patients:**

3 **Comparison of four waves of the pandemic in Japan**

4

5 Koichi Furukawa, MD^{1*}, Lidya Handayani Tjan, MD^{1*}, Silvia Sutandhio, MD¹, Yukiya

6 Kurahashi, MD¹, Sachiyo Iwata, MD, PhD², Yoshiki Tohma, MD³, Shigeru Sano, MD,

7 PhD³, Sachiko Nakamura, MD⁴, Mitsuhiro Nishimura, PhD¹, Jun Arii, DVM, PhD¹,

8 Tatsunori Kiri, MD, PhD⁵, Masatsugu Yamamoto, MD, PhD⁵, Tatsuya Nagano, MD,

9 PhD⁵, Yoshihiro Nishimura, MD, PhD⁵, Yasuko Mori, MD, PhD¹.

10

11 ¹Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate

12 School of Medicine, Kobe, Hyogo 650-0017, Japan

13 ²Division of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center,

14 Kakogawa 675-0003, Japan

15 ³Acute Care Medical Center, Hyogo Prefectural Kakogawa Medical Center, Kakogawa

16 675-0003, Japan

17 ⁴Division of General Internal Medicine, Hyogo Prefectural Kakogawa Medical Center,

18 Kakogawa 675-0003, Japan

1 ⁵Division of Respiratory Medicine, Department of Internal Medicine, Kobe University

2 Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan

3 ***Contributed equally to this work.**

4

5 **Corresponding author:**

6 Prof. Yasuko Mori

7 Division of Clinical Virology, Center for Infectious Disease,

8 Kobe University Graduate School of Medicine.

9 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo Japan, 650-0017

10

11

12

13

1

2 **ABSTRACT**

3 In March 2021, Japan is facing a 4th wave of SARS-CoV-2 infection. To prevent further
4 spread of infection, sera cross-neutralizing activity of patients previously infected with
5 conventional SARS-CoV-2 against novel variants is important but is not firmly
6 established. We investigated the neutralizing potency of 81 COVID-19 patients' sera
7 from 4 waves of pandemic against SARS-CoV-2 variants using their authentic viruses.
8 Most sera had neutralizing activity against all variants, showing similar activity against
9 B.1.1.7 and D614G, but lower activity especially against B.1.351. In the 4th wave,
10 sera-neutralizing activity against B.1.1.7 was significantly higher than that against any
11 other variants, including D614G. The cross-neutralizing activity of convalescent sera
12 was effective against all variants but was potentially weaker for B.1.351.

13

14 **Key Words:** SARS-CoV-2, COVID-19, variant, reinfection, neutralizing activity

15

1 **BACKGROUND**

2 The coronavirus disease 2019 (COVID-19) pandemic declared by the World
3 Health Organization (WHO) in March 2020 continues to affect all countries around the
4 world. In efforts to control the pandemic, several vaccine platforms have been
5 developed based on the original severe acute respiratory syndrome coronavirus 2
6 (SARS-CoV-2) (Wuhan-1) as the template, and these vaccines have been shown to be
7 effective for reducing the COVID-19 outbreak [1-3].

8 However, the evolution of SARS-CoV-2 has continued since its initial emergence.
9 By the beginning of April 2020, a variant bearing a D614G mutation with evidence of
10 increased infectivity had become dominant [4]. The SARS-CoV-2 variant B.1.1.7, first
11 detected in Kent and Great London in September 2020, has now spread to many
12 countries worldwide with evidence indicating an increased mortality rate [5, 6]. In
13 addition to D614G and several mutations in other areas of the genome, B.1.1.7 bears
14 eight mutations in the spike gene including deletions in the N-terminal domain
15 (Δ H69/ Δ V70, Δ 144) and amino acid substitutions in the receptor binding domain
16 (N501Y) [7, 8].

17 The SARS-CoV-2 variant B.1.351 was first detected in specimens collected from
18 South Africa in October 2020, and it has rapidly become the predominant variant

1 circulating throughout South Africa [9]. Among the nine mutations in the spike gene in
2 this variant, there are three biologically important mutations: K417N, E484K, and
3 N501Y [7]. Importantly, there is growing evidence that the B.1.351 variant has the
4 ability to escape from the neutralizing antibody elicited against the original
5 SARS-CoV-2 infection and currently available vaccines [7, 10-12].

6 The SARS-CoV-2 variant P.1, which was first detected in Japan in early January
7 2021 from four individuals with a history of traveling to Brazil, had become the
8 predominant variant circulating in Brazil by January 2021 [13]. It bears 12 mutations in
9 the spike gene, including K417T, E484K, and N501Y [14], which are the same three
10 amino acid substitutions as those found in B.1.351. Interestingly, variant P.1 showed
11 less resistance to a neutralizing antibody induced by natural infection or vaccination
12 compared to a similar variant, B.1.351 [15].

13 The emergence of these variants poses a tremendous challenge to the control of
14 the SARS-CoV-2 pandemic. In addition, the B.1.351 and P.1 variants carry the E484K
15 mutation that is responsible for evasion from the monoclonal antibody against original
16 SARS-CoV-2, further compromising the currently available therapy against this virus
17 [16].

18 As of May 2021, Japan has experienced four waves of the COVID-19 pandemic,

1 beginning in April 2020; the number of total confirmed cases is over 690,000 and there
2 have been more than 11,000 deaths due to COVID-19 in Japan alone [17]. The growth
3 rate of the number of infected individuals in the 4th wave is much faster than those of
4 the 1st to 3rd waves so far, and there is concern about the possibility of a collapse of the
5 healthcare system. SARS-CoV-2 genome surveillance has revealed that D614G_KR and
6 its lineages were the predominating circulating viruses responsible for the 1st to 3rd
7 waves of the pandemic in Japan, but the introduction of the R1 and B.1.1.7 variants in
8 late 2020 has replaced the previously existing strains and may be responsible for the 4th
9 wave [18]. The B.1.351 and P.1 variants have also been detected in Japan, although no
10 trend toward an increasing dominance of these variants has been observed thus far [19].

11 It is not yet known to what extent the serum of patients previously infected with
12 original SARS-CoV-2 might confer protection against these rapidly emerging variants.
13 In this study, we investigated the neutralizing potency of serum from patients infected
14 during the 1st to 4th waves of the pandemic against SARS-CoV-2 variants D614G,
15 B.1.1.7, B.1.351, and P1, using authentic virus. This research is imperative to
16 understand whether individuals who have recovered from COVID-19 could be protected
17 from reinfection by newly emerging variants. This research might also help predict the
18 potency of using plasma from individuals who recovered from the conventional type or

1 any variants of SARS-CoV-2 as a donor if convalescent plasma therapy can be used for
2 COVID-19 patients infected by the other variants.

3

4 **METHODS**

5 **Diagnosis of COVID-19**

6 COVID-19 diagnoses were based on the polymerase chain reaction (PCR) detection of
7 the SARS-CoV-2 genome in nasopharyngeal swab samples. Disease severity was
8 defined as follows: Symptomatic COVID-19 cases without evidence of pneumonia or
9 hypoxia were classified as mild. Cases in patients with clinical signs of pneumonia were
10 classified as moderate (oxygen saturation as measured by pulse oximetry, $\geq 90\%$ with
11 room air) or as severe (respirations $>30/\text{min}$, severe respiratory distress, or oxygen
12 saturation $<90\%$ with room air). Patients who needed mechanical ventilation were
13 classified as critical.

14

15 **Definitions of the waves of the COVID-19 pandemic in Japan**

16 The period from the 1st wave to the 4th wave of the COVID-19 pandemic was defined
17 based on the change in the number of infected people on a single day in Japan. The 1st
18 wave was from March 1st to the end of June 2020; the 2nd wave was from July 1st to

1 the end of October 2020; the 3rd wave was from November 1st 2020 to the end of
2 February 2021, and the 4th wave was the period beginning March 1st 2021 [17].

3

4 **Participant recruitment**

5 From March 2020 to May 2021, blood samples were collected from patients who
6 became infected with SARS-CoV-2 and were hospitalized at Hyogo Prefectural
7 Kakogawa Medical Center (Hyogo, Japan). We selected serum of convalescent patients
8 with different disease severities who were already confirmed to have neutralizing
9 activity against the SARS-CoV-2. In May 2020, the serum of 24 healthy individuals
10 were collected and confirmed to have no antibody against SARS-CoV-2; these sera
11 were used as the negative control group [20]. This study was a retrospective
12 observational investigation and was carried out after written consent was obtained from
13 the subjects or by the opt-out method when it was difficult to get written consent due to
14 the disease severity. No statistical methods were used to predetermine the sample size.

15

16 **Measurement of neutralizing activity against SARS-CoV-2**

17 Neutralization was performed as described [21]. Briefly, the neutralizing activity of
18 each serum sample was evaluated by a neutralization assay against each living

1 SARS-CoV-2 variant (D614G, B.1.1.7, P.1, or B.1.351) in a biosafety level 3 laboratory.
2 Vero E6 (TMPRSS2) cells were used [22]. The neutralizing antibody titer was
3 determined as the highest serum dilution that did not show any cytopathic effects.

4

5 **Preparation of SARS-CoV-2 variants**

6 We used the SARS-CoV-2 Biken-2 (B2) strain with a D614G mutation as a
7 conventional variant. It was provided by the Research Foundation for Microbial
8 Diseases of Osaka University (BIKEN). The three variants B.1.1.7, P.1, and B.1.351
9 were isolated and provided by the National Institute of Infectious Disease, Japan.

10

11 **Statistical analysis**

12 GraphPad Prism software (ver. 8.4.3) was used for the statistical analysis and
13 preparation of figures. The Friedman test was used to compare the neutralizing antibody
14 titer among the four variants. The Kruskal-Wallis test was used to compare the
15 neutralizing antibody titer among different disease severity groups. Results were
16 considered significant at a p-value <0.05.

17

18 **Ethical approval**

1 This study was approved by the ethical committees of Kobe University Graduate School
2 of Medicine (approval code: B200200) and Hyogo Prefectural Kakogawa Medical
3 Center.

4

5 **RESULTS**

6 **Patient characteristics**

7 We examined a total of 81 sera of patients with different disease severities who were
8 already confirmed to have neutralizing activity against B2 strain, which is a D614G
9 variant. The median number of days between the onset of symptoms and the collection
10 of serum samples (days post-onset, dpo) was 26 days. Overall, 62% of the patients were
11 male, 38% were female, and the median age was 64 years. The asymptomatic/mildly
12 infected group was comprised of 25 patients, 19 patients were moderate/severe, and the
13 remaining 37 patients were in the critical infection group. The most common medical
14 histories were hypertension and diabetes, in 28.4% of the patients each.

15 Eleven patients had received antiviral treatment with favipiravir or lopinavir
16 (both for six patients and favipiravir for five patients), and 42 patients received steroid
17 treatment. A comparison of the four waves revealed that the 2nd wave (with 20 patients)
18 contained only one critical patient, whereas all 20 patients in the 4th wave were critical

1 and were mostly (75%) male. In addition, antiviral treatment was mainly prescribed for
2 the patients in the 1st wave, whereas steroids were mainly used in the 2nd wave onward.

3

4 **Neutralizing activity against all variants in all patients**

5 Most of the 81 sera had neutralizing activity against the four variants, although the
6 activity values varied (Fig. 1). The mean neutralizing antibody titer for the D614G
7 variant was 80, and that for the B.1.1.7 variant was 111. The neutralizing titer of B.1.1.7
8 seemed to be higher than that of D614G, but the difference was not significant. In
9 contrast, the mean neutralizing antibody titer against P.1 was 44 and that against or
10 B.1.351 was 21, and each of these values was lower than that for D614G, especially in
11 B.1.351 (3.8x, $p < 0.0001$).

12

13 **Neutralizing activity against all variants in each wave**

14 From the 1st wave to the 3rd wave, the neutralizing activity against B.1.1.7 variant was
15 similar or slightly low compared to that against D614G, whereas it was higher in the 4th
16 wave (increased 4x, $p = 0.0009$). In addition, the neutralizing activity against B.1.1.7
17 was also higher than that against P.1 or B.1.351 variant in the 4th wave. In all waves,
18 the neutralizing activity against B.1.351 variant was lower than those against the other

1 three variants (Fig. 2).

2

3 **Neutralizing activity against each variant by severity**

4 The sera of all of the COVID-19 patients showed neutralizing activity against the
5 D614G and B.1.1.7 regardless of the severity of the patients' symptoms. A significantly
6 lower neutralizing titer against D614G, B.1.1.7, P.1, or B.1.351 was observed in the
7 serum of the asymptomatic/mild COVID-19 patients compared to that of the critical
8 patients (four- to ninefold lower, $p < 0.0001$) (Fig. 3a–d).

9 Interestingly, almost all of the sera from the asymptomatic/mild infected group,
10 with the exception of three cases, had neutralizing activity against all tested variants.
11 Three asymptomatic/mild cases and one case in the severe-infection group with low
12 neutralizing activity against D614G (titer 8 or 16) did not show any neutralizing activity
13 against P.1 or B.1.351 (Fig. 3c,d).

14

15 **DISCUSSION**

16 In Japan, the 4th wave of SARS-CoV-2 arrived in March 2021, and the presence of the
17 variant B.1.1.7 has increased in this wave. It is suspected that the conventional D614G
18 variant has already been almost completely replaced by B.1.1.7. In addition, P.1 and

1 B.1.351 have also been identified in Japan, and there is thus a possibility of a further
2 spread of infection in the future. Given the recent emergence of the B.1.1.7, P.1, and
3 B.1.351 variants, the cross-neutralization of these variants by previous pandemic sera
4 remains to be clarified. To predict and help prevent the further spread of SARS-CoV-2
5 infection, it is necessary to determine whether the neutralizing activity in COVID-19
6 patients infected with the D614G have similar activity against the newly emerging
7 variants.

8 In the present study, regardless of the patients' infection time (wave) and disease
9 severity, most of their sera had neutralizing activity against the four variants (D614G,
10 B.1.1.7, P.1, and B.1.351) although the neutralizing activity values varied. Some
11 individuals that showed high neutralizing activity against D614G and B.1.1.7, also had
12 the high activity against P.1 and B.1.351, indicating that individuals infected with
13 D614G or B.1.1.7 also could have the neutralizing antibody against P.1 and B.1.351.

14 Although we observed no significant difference between the neutralizing activity
15 of sera against B.1.1.7 and D614G in all patients, the values of neutralizing activity
16 against P.1 and B.1.351 were lower than that against D614G, and the neutralizing
17 activity against B.1.351 in particular was much lower. This means that the neutralizing
18 activities of sera from previously infected patients was also seen against the B.1.1.7 but

1 was potentially weaker against the P.1 and B.1.351. As one of the potential explanations
2 for this finding, we note that N501Y substitution (which is common among these three
3 variants) may enhance the binding to ACE2, but its antigenic effects are limited and it
4 may little affects the neutralizing activity of the antibodies [23, 24]. However, E484K
5 mutation which is found both in P.1 and B.1.351, but not in either D614G and B.1.1.7,
6 has been reported to affect the binding of serum polyclonal neutralizing antibodies [16].

7 On the other hand, because P.1 and B.1.351 have similar mutations in their RBD
8 (including E484K, K417T/N, and N501Y), it might be thought that the neutralization of
9 both variants would be affected similarly. However, our present analyses demonstrated
10 that while some sera of individuals showed similar or high neutralizing activity against
11 P.1 compared to those against D614G, the activity against B.1.351 was consistently
12 lower than that against D614G, indicating that B.1.351 might avoid the neutralization
13 more effectively by means other than mutations of the RBD, such as the amino acid
14 deletions (242-244 del) and substitutions (D80A, R246I) in the N terminal domain
15 (NTD) [7, 11, 25].

16 Interestingly, although we observed that the neutralizing activity against the
17 B.1.1.7 seemed to be similar to or slightly lower than that against D614G from the 1st to
18 3rd waves in Japan, its activity against B.1.1.7 was higher than that against D614G, P.1,

1 and B.1.351 in the 4th wave, indicating an epidemic of B.1.1.7. In particular, the
2 neutralizing activities against P.1 and B.1.351 were significantly lower than that for
3 B.1.1.7. Regarding this result, some other groups have also reported that antibodies
4 elicited by B.1.1.7 infection exhibited significantly reduced recognition and
5 neutralization of parental (Wuhan) strain or B.1.351 compared to B.1.1.7 [26, 27]. Our
6 result may suggest that the mutations in B.1.1.7 could cause the conformational change
7 of its spike protein, which affects the immune recognition for D614G.

8 The correlation between serum neutralization activity against D614G and clinical
9 severity has been described [28-31], and our present findings revealed a similar
10 correlation for three other variants. Even among the asymptomatic/mild patients, all had
11 neutralizing activity against B.1.1.7 and most also had neutralizing activity against P.1
12 and B.1.351.

13 Our results suggest that natural infection with each SARS-CoV-2 variant prompts
14 the body to make antibodies that recognize the infecting strain most robustly, with
15 various degrees of cross-recognition of other strains. The efficacy of convalescent
16 plasma therapy remains controversial, but it may be considered to use the convalescent
17 sera induced by conventional strain for high risk patients infected with B.1.1.7 or P.1
18 [32-34]. Individuals recovered from the infection of 4th wave may not completely

1 protect against reinfection with the other SARS-CoV-2 variants in the future,
2 especially in asymptomatic or mild cases which have low neutralizing activity. Our
3 findings may indicate that the cross-neutralization could work to protect against the
4 induction of severe symptoms when an individual is reinfected by new variants. Further
5 studies are required to address this and many other questions about the variants that
6 continue to arise.

7

8 **Funding:** This work was supported by Hyogo Prefectural Government.

9

10 **Acknowledgments:** We thank Kazuro Sugimura MD, PhD (Kobe University and
11 Hyogo Prefectural Hospital Agency) for his full support to promote this study. We
12 express our sincere gratitude for cooperation and participation of staffs of Hyogo
13 Prefectural Kakogawa Medical Center. We thank Research Foundation for Microbial
14 Diseases of Osaka University (BIKEN), Osaka University for providing SARS-CoV-2
15 B2 strain. We thank the National Institute of Infectious Disease Japan for providing
16 SARS-CoV-2 B.1.1.7, P.1, and B.1.351 variants.

17

18 **Conflicts of Interest:** The authors declare no conflicts of interest with respect to this.

1

2 **References :**

- 3 1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and
4 Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and
5 mortality in older adults in England: test negative case-control study. *BMJ* **2021**;
6 373:n1088.
- 7 2. Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine
8 candidates. *Clin Immunol* **2021**; 222:108634.
- 9 3. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks
10 in the United States. *medRxiv* 2020::2020.11.27.20240051. Available at:
11 <https://www.medrxiv.org/content/10.1101/2020.11.27.20240051v2>. Accessed 20 May, 2021.
- 12 4. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence
13 that D614G Increases Infectivity of the COVID-19 Virus. *Cell* **2020**; 182:812-27. e19.
- 14 5. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of
15 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort
16 study. *BMJ* **2021**; 372:n579.
- 17 6. Davies NG, Jarvis CI, Edmunds WJ, et al. Increased mortality in community-tested cases
18 of SARS-CoV-2 lineage B.1.1.7. *Nature* **2021**; 593:270-4.

- 1 7. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and
2 B.1.1.7. *Nature* **2021**; 593:130–5.
- 3 8. Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent
4 SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological*.
5 Available [https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-co](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-co-v-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
6 [v-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-co-v-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563). Accessed 20 May,
7 2021 2021.
- 8 9. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe
9 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike
10 mutations in South Africa. *medRxiv* 2020;:2020.12.21.20248640. Available at:
11 <https://doi.org/10.1101/2020.12.21.20248640>.
- 12 10. Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization
13 by convalescent plasma. *Nature* **2021**; 593:142–6.
- 14 11. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant
15 B.1.351 from natural and vaccine-induced sera. *Cell* **2021**; 184:2348–61.e6.
- 16 12. Bian L, Gao F, Zhang J, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and
17 response strategies. *Expert Rev Vaccines* **2021**:1–9.
- 18

- 1 13. Faria NR, Claro IM, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2
2 lineage in Manaus: preliminary findings. *virological*. Available at:
3 [https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586)
4 [in-manaus-preliminary-findings/586](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586). Accessed 20 May, 2021.
- 5 14. National Institute of Infectious Diseases. Brief report: New Variant Strain of
6 SARS-CoV-2 Identified in Travelers from Brazil. 12 January, 2021. Available at:
7 <https://www.niid.go.jp/niid/en/2019-ncov-e/10108-covid19-33-en.html>. Accessed 20 May,
8 2021.
- 9 15. Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of
10 SARS-CoV-2. *Cell* **2021**.
- 11 16. Jangra S, Ye C, Rathnasinghe R, et al. SARS-CoV-2 spike E484K mutation reduces antibody
12 neutralisation. *Lancet Microbe* **2021**.
- 13 17. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at:
14 <https://covid19.who.int/region/wpro/country/jp>. Accessed 20 May, 2021.
- 15 18. Tokumasu R, Weeraratne D, Snowdon J, Parida L, Kudo M, Koyama T. Introductions and
16 evolutions of SARSCoV-2 strains in Japan. *medRxiv* 2021;:2021.02.26.21252555. Available
17 at: <https://www.medrxiv.org/content/10.1101/2021.02.26.21252555v1>. Accessed 20 May,
18 2021.

- 1 19. Sharif N, Ahmed SN, Opu RR, et al. Impact of meteorological parameters and population
2 density on variants of SARS-CoV-2 and outcome of COVID-19 pandemic in Japan. *Epidemiol*
3 *Infect* **2021**; 149:e103.
- 4 20. Nagano T, Arii J, Nishimura M, et al. Diligent Medical Activities of a Publicly
5 Designated Medical Institution for Infectious Diseases Pave the Way for Overcoming
6 COVID-19: A Positive Message to People Working at the Cutting Edge. *Clin Infect Dis* **2021**;
7 72:723-4.
- 8 21. Furukawa K, Arii J, Nishimura M, et al. Seroepidemiological Survey of the Antibody
9 for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at
10 Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. *JMA J* **2021**; 4:41-9.
- 11 22. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by
12 TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A* **2020**; 117:7001-3.
- 13 23. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K
14 and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med* **2021**; 27:620-1.
- 15 24. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies
16 against spike mutants from global SARS-CoV-2 variants. *bioRxiv* **2021**.
- 17 25. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by
18 South African COVID-19 donor plasma. *Nat Med* **2021**; 27:622-5.

- 1 26. Faulkner N, Ng KW, Wu M, et al. Reduced antibody cross-reactivity following infection
2 with B.1.1.7 than with parental SARS-CoV-2 strains. *bioRxiv* 2021;:2021.03.01.433314.
3 Available at: <https://www.biorxiv.org/content/10.1101/2021.03.01.433314v1>. Accessed 20
4 May, 2021.
- 5 27. Brown JC, Goldhill DH, Zhou J, et al. Increased transmission of SARS-CoV-2 lineage
6 B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway
7 cells or antibody escape. *bioRxiv* 2021;:2021.02.24.432576. Available at:
8 <https://www.biorxiv.org/content/10.1101/2021.02.24.432576v1>. Accessed 20 May, 2021.
- 9 28. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic
10 SARS-CoV-2 infections. *Nat Med* **2020**; 26:1200-4.
- 11 29. Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected
12 patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
13 *Cell Mol Immunol* **2021**; 18:318-27.
- 14 30. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies
15 predict disease severity and survival. *Cell* **2021**; 184:476-88.e11.
- 16 31. Tjan LH, Nagano T, Furukawa K, et al. The Neutralizing Antibody Response against Severe
17 Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients
18 with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists

- 1 Despite Viral Disappearance in Critical Patients. *JMA J* **2021**; 4:1-7.
- 2 32. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent
3 Severe Covid-19 in Older Adults. *N Engl J Med* **2021**; 384:610-8.
- 4 33. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe
5 COVID-19 patients. *Proc Natl Acad Sci U S A* **2020**; 117:9490-6.
- 6 34. Group RC. Convalescent plasma in patients admitted to hospital with COVID-19
7 (RECOVERY): a randomised controlled, open-label, platform trial. *Lancet* **2021**.

8

9 **Figure legends**

10 **Fig. 1.** Neutralization activity against SARS-CoV-2 variants. Sera of 81 patients who
11 had recovered from COVID-19 were tested for neutralizing activity against the
12 SARS-CoV-2 variants D614G, B.1.1.7, P.1, and B.1.351. The neutralizing antibody titer
13 is represented by the logarithmic scale of the highest serum dilution that did not show
14 any cytopathic effects. **a:** Box plot of the neutralizing antibody titers with the minimum,
15 first quartile, median, third quartile, and maximum values. **b:** Changes in the antibody
16 titer for each patient. The titer of the same patient is connected by a line. The Friedman
17 test was used, and two-tailed p-values were calculated. *p<0.05, **p<0.01.

18

1 **Fig. 2.** The neutralizing activity against all variants in each wave. The neutralizing
2 antibody titers of sera against D614G, B.1.1.7, P.1, and B.1.351 were compared in the
3 1st wave (from March 1st to June 2020, **a**), 2nd wave (from July 1st to October 2020, **b**),
4 3rd wave (from November 1st 2020 to February 2021, **c**) and 4th wave (after March 1st
5 2021, **d**). The Friedman test was used, and two-tailed p-values were calculated. * $p < 0.05$,
6 ** $p < 0.01$.

7


8 **Fig. 3.** The neutralizing activity against each variant by disease severity. The
9 neutralizing antibody titer against **(a)** D614G, **(b)** B.1.1.7, **(c)** P.1 and **(d)** B.1.351 in
10 patient's sera with different severity groups. The Kruskal-Wallis test was used, and
11 two-tailed p-values were calculated. * $p < 0.05$, ** $p < 0.01$.

12


13

Neutralizing antibody titer (log₂)

a.



b.



SARS-CoV-2 Variants

